Smith & Nephew (SN.)

Sector:

Health Care

Index:

FTSE 100

NULL
   
  • Closing Price Chg:
    -10.00p
  • 52 Week High: NULL
  • 52 Week Low: 918.00p
  • Currency: UK Pounds
  • Shares Issued: 875.96m
  • Volume: 0
  • RiskGrade: 173
  • Beta: 0.00

Smith & Nephew at four-month high as activist investor Cevian buys stake

By Benjamin Chiou

Date: Thursday 04 Jul 2024

LONDON (ShareCast) - (Sharecast News) - Swedish activist investor Cevian Capital has purchased a 5% stake in Smith & Nephew, causing shares in the medical equipment manufacturer to surge to a four-month high on Thursday.
In a 'notification of major holdings' regulatory filing on Thursday, Smith & Nephew revealed that Cevian now holds 43.9m shares in the company.

The purchase of the 5.021% stake is Cevian's first investment in the FTSE 100 company and makes the Swedish firm its third-largest shareholder. At Wednesday's closing price of 986.2p, the stake would have been worth around £433m.

The purchase by Cevian, whose stated strategy is to acquire large minority stakes in European listed companies "and work as an owner to advance long-term and sustainable value creation", follows an 8% drop in the share price since the start of 2024.

Smith & Nephew's business has been impacted severely by the pandemic over recent years, as demand for its orthopaedic products reduced on the back of a huge number of cancelled elective procedures. Prior to Thursday, the stock had dropped 18% over the past year and 43% over the past five years.

"Activist investors often circle a struggling company so the news Sweden's Cevian has taken a stake in medical devices firm Smith & Nephew shouldn't come as a huge surprise," said AJ Bell investment director Russ Mould.

"Cevian has previously taken positions in UBS, Vodafone and Aviva in an attempt to force change and the case for doing so at Smith & Nephew is presented by a near-40% decline in the share price over the last five years. The positive share price reaction to Cevian taking a position in Smith & Nephew demonstrates the market thinks an outside catalyst for a shake-up of the business would be no bad thing," Mould said.

He added that Smith & Nephew's improvement plan announced in 2022 has "not yet resulted in a material improvement in earnings and profitability", made worse by a "weak showing" in the US market.

The stock was up 7.3% at 1,058.62p by 1051 BST, a level not seen since 15 March.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Smith and Nephew Market Data

Currency UK Pounds
Share Price NULL
Closing Price Change -10.00p
% Change 0.00 %
52 Week High NULL
52 Week Low 918.00p
Volume 0
Shares Issued 875.96m
Beta 0.00
RiskGrade 173

Smith and Nephew Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
90.94% below the market average90.94% below the market average90.94% below the market average90.94% below the market average90.94% below the market average
9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average
Price Trend
33.55% above the market average33.55% above the market average33.55% above the market average33.55% above the market average33.55% above the market average
54.29% above the sector average54.29% above the sector average54.29% above the sector average54.29% above the sector average54.29% above the sector average
Income
53.27% below the market average53.27% below the market average53.27% below the market average53.27% below the market average53.27% below the market average
75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average
Growth
11.50% above the market average11.50% above the market average11.50% above the market average11.50% above the market average11.50% above the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 9
Sell 0
Strong Sell 0
Total 16
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Smith and Nephew Dividends

  Latest Previous
  Final Interim
Ex-Div 27-Mar-25 03-Oct-24
Paid 28-May-25 08-Nov-24
Amount 23.10¢ 14.40¢

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Smith and Nephew Key Personnel

CEO Deepak Nath
CFO John Rogers

Top of Page